© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to November
oral plasmodium eEF2 inhibitor
Ph. I candidate for malaria treatment
from phenotypic screen & optimization
Merck Institute for Pharmacometrics
13. The Merck Institute antimalarial compound, M5717, is the first plasmodium eEF2 inhibitor to reach clinical development, and is a good example of an orally available dibasic compound as well…
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.